Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 22, 2026 | September 24, 2026 |
| Alector, Inc.ALEC · Entity 6051 | President and COO | December 10, 2021 | December 15, 2021 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, Corp Dev & Strategy | February 20, 2019 | February 22, 2019 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 23,792 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 292 · Balance 29,223 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F2: This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 614 · Balance 28,609 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F3: This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 1,325 · Balance 27,284 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F4: This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 2,270 · Balance 25,014 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F5: This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 1,222 · Balance 23,792 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. F6: This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $77.76 to $78.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.075 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.08 to $81.0769, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.08 to $82.0791, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.08 to $82.56, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Alector, Inc.
Report date December 10, 2021 · Filed December 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,598 |
Ending reported balance
After 2021-12-13 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2021-12-10 · Exercise / conversion · Acquired 75,000 · Balance 177,598 Row 2 · 2021-12-10 · Sale · Disposed 66,126 · Balance 111,472 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Row 3 · 2021-12-10 · Sale · Disposed 8,874 · Balance 102,598 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.54, inclusive. Row 4 · 2021-12-13 · Exercise / conversion · Acquired 75,000 · Balance 177,598 Row 5 · 2021-12-13 · Sale · Disposed 64,102 · Balance 113,496 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.56 to $21.55, inclusive. Row 6 · 2021-12-13 · Sale · Disposed 10,898 · Balance 102,598 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.565 to $21.92, inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.23 · Expires 2029-12-31 | Direct | 380,187 |
Reported balance
After 2021-12-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-10 · Exercise / conversion · Disposed 75,000 · Balance 380,187 F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.23 · Expires 2029-12-31 | Direct | 305,187 |
Reported balance
After 2021-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-13 · Exercise / conversion · Disposed 75,000 · Balance 305,187 F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.54, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.56 to $21.55, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.565 to $21.92, inclusive.
F6: One-fourth of the shares subject to the option grant vested on December 9, 2020, and 1/48th vest monthly thereafter.
Theravance Biopharma, Inc.
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 97,198 |
Reported balance
After 2019-02-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-20 · Tax withholding · Disposed 5,763 · Balance 97,198 F1: Includes 1,731 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,731 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,951 |
Ending reported balance
After 2026-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,691 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Row 2 · 2026-05-18 · Sale · Disposed 5,740 · Balance 27,951 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 5, 2020 20:27 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 189,213 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001209191-20-053599 · doc4.xml · derivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,213 Underlying: Common Stock · 189,213 shares Expires 2030-09-30 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the one month anniversary of October 1, 2020 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the shares shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a service provider to the Issuer through each such date. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $76.58 | $0.00 |
DisclosureSEC source: 0001209191-20-039409 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 17:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039409 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021 Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,432 | $0.00 Strike: $88.42 | $0.00 |
DisclosureSEC source: 0001209191-20-037275 · doc4.xml · derivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,432 Underlying: Class A Common Stock · 4,432 shares Expires 2030-06-15 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| January 01, 2020 Filed Jan 27, 2020 22:12 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001209191-20-005031 · doc4.xml · derivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option shall vest on December 9, 2020, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0000899243-19-023627 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2029-08-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on September 7, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0000899243-19-023627 · doc4.xml · derivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 100,000 shares Expires 2029-08-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on September 7, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001209191-19-036829 · doc4.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036829 · doc4.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,763 | $27.00 | $155,601.00 |
DisclosureSEC source: 0001179110-19-002431 · edgar.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,198 F1 · balance_after: Includes 1,731 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $48.85 | $0.00 |
DisclosureSEC source: 0001209191-19-006617 · doc4.xml · derivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-30 F1 · derivative.exercise_date: The option shall vest with respect to 1/36th of the shares monthly such that the option shall be fully vested on the third anniversary of the grant date. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:41 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,770 | $29.09 | $255,119.30 |
DisclosureSEC source: 0001179110-18-002613 · edgar.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,230 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002128 · edgar.xml · nonDerivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · shares: On August 1, 2017, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions from August 1, 2017 through December 31, 2020 and continued employment. On February 12, 2018, the performance conditions applicable to 25,000 shares were deemed achieved and such shares will vest on February 20, 2018. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002128 · edgar.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 22:12 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $31.93 | $0.00 |
DisclosureSEC source: 0001179110-17-011060 · edgar.xml · derivative · entry 2 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Ordinary Shares · 170,000 shares Expires 2027-07-31 F1 · derivative.exercise_date: This option may be exercised with respect to the first 25% of the shares subject to this option when optionee completes 12 months of continuous service after the Grant Date. This option may be exercised with respect to an additional 1/48th of the shares subject to this option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the Grant Date provided optionee has remained in continuous service through such date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 22:12 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011060 · edgar.xml · nonDerivative · entry 1 SULIMAN SHEHNAAZ · CIK 0001713070 · SVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.